<DOC>
	<DOCNO>NCT01382550</DOCNO>
	<brief_summary>The aim study estimate incidence spontaneous provoke recurrent VTE bleed event 10-year follow-up subject experience first VTE stratify accord % AT level treatment schedule ( long-term v 6-12 month oral anticoagulation+transient prophylaxis high risk period )</brief_summary>
	<brief_title>Prevention Thrombosis Recurrence Patients With Low Circulating Levels Antithrombin .</brief_title>
	<detailed_description>Study population : subject recent ( &lt; 3 month ) first VTE event enrol long-term follow-up . Clinical visit perform every 4-6 month ( average ) . In case , objective diagnosis achieve compression ultrasonography , diagnosis base lack compressibility one venous segment . PE document ventilation/perfusion lung scan spiral compute tomography ( CT ) . For subject , information pregnancy , active malignancy , recent ( &lt; 3 mo ) surgery trauma , fracture , immobilization , acute medical illness , use oral contraceptive , long-distance travel , personal family history arterial and/or venous thrombosis repeat birth loss collect . In presence least one previous risk factor , VTE define secondary otherwise idiopathic . Further information , collect whole population train staff , follow : gender , age , weight , height , body mass index ( BMI ) , waist circumference , personal history symptomatic atherosclerosis ( i.e . ischemic stroke , transient ischemic attack , acute myocardial infarction , angina , intermittent claudication ) , arterial hypertension , use antihypertensive drug , diabetes mellitus , use antidiabetic drug , hyperlipidemia , use statin , smoke habit ( use cigarettes/d ) , current use heparin , use oral anticoagulant ( long ) antiplatelet drug ( long ) , chronic consumption drug . All information collect trained staff admission follow-up visit ( every 4-6 month ) . Exclusion criterion : miss data follow-up ; contraindication lack compliance oral anticoagulation ( OAT ) , lack informed consent ; history previous VTE event ; indication continuous oral anticoagulation ( e.g. , artificial heart valve chronic atrial fibrillation ) ; event occur pregnancy , malignancy , puerperium , oral contraceptive intake , hormone replacement therapy ; deficiency Prot . C Prot S combine inhibitor deficiency . Laboratory Studies All laboratory evaluation carry least 2 week cessation anticoagulant therapy switch low-molecular weight heparin ( LMWH ) treatment . Antithrombin ( AT ) functional activity measure VTE patient stratify 3 subgroup AT % ( 1st : &lt; 70 % , 2nd : 70-80 , 3rd : &gt; 81 % ) . AT measurement confirm second sample collect 3 month later . In case discrepancy result 2 test , third sample collect . Protein C S ; antiphospholipid antibody ( IgG IgM ) ; homocysteine , factor V Leiden prothrombin 20210A polymorphism determine use commercially available kit technician unaware patient ' treatment assignment clinical course . Antithrombotic treatment The antithrombotic treatment decide accord usual practice enrol Center . The duration initial treatment parenteral anticoagulation ( Low Molecular Weight Heparin Fondaparinux ) , begin oral anticoagulation ( OAT ) Vit K inhibitor International Normalized Ratio ( INR ) target record . According Center indication OAT duration ( 6 month , 12 month long-lasting ) record population stratify accordingly . The length therapy count date stable prothrombin time within target INR range achieve . The occurrence surgery , trauma , prolong immobilization ( &gt; 7 day ) , pregnancy ( VTE risk period ) follow-up use adequate anti-thrombotic prophylaxis record . Follow-up Subjects followed-up 3 , 6 , 12 month enrollment least every 6 month thereafter either visit Center telephone contact . INR value report telephone twice monthly . At visit patient ask new symptom VTE bleed manifestation . When appropriate , clinical assessment make diagnostic test perform . Information major minor bleeding oral anticoagulation collect whole sample . Major bleeding define hemorrhage either retroperitoneal intracranial associate decrease hemoglobin least 2.0 g per deciliter require either transfusion least 2 unit blood ( red cell ) invasive procedure , include surgery , stop warrant permanent OAT withdrawing . Study end point The incidence objectively document recurrent VTE ( DVT and/or PE ) life-long follow-up primary outcome study . Contralateral DVT PE compute recurrence . Ipsilateral DVT adjudicate recurrent result test worse obtain previous test thrombus diagnose another venous district leg . DVT arm ; CT MRI-documented occlusion cerebral/abdominal vein ; ultrasound-documented thrombosis great saphenous vein leg involve first appearance also define recurrence . The total ( minor major ) bleed occurrence life-long follow-up represent safety end-point study analyze accord thrombolysis myocardial infarction ( TIMI ) bleed score . Sample size Assuming 20:1:1 sample size ratio AT % subgroup ( AT % &gt; 80 % ; AT % =70-80 % ; AT % &lt; 70 % , respectively ) , detect increase incidence recurrent event 0.3 control population ( AT % &gt; 80 % ) 0.6 two subgroup ( AT % =70-80 % AT % &lt; 70 % ) , sample size 900 subject need ( power= 95 % ; Î±=0.025 , allow two independent comparison ) . Expected result Among individual history first VTE stratify accord AT % level , risk/benefit analysis study help identify group ( ) individual strong indication long-term oral anticoagulation .</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Antithrombins</mesh_term>
	<mesh_term>Antithrombin III</mesh_term>
	<criteria>Recent ( &lt; 3 month ) First VTE event miss data followup ; contraindication lack compliance oral anticoagulation ( OAT ) , lack informed consent ; history previous VTE event ; indication continuous oral anticoagulation ( e.g. , artificial heart valve chronic atrial fibrillation ) ; event occur pregnancy , malignancy , puerperium , oral contraceptive intake , hormone replacement therapy ; deficiency Prot . C Prot S combine inhibitor deficiency .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>antithrombin</keyword>
	<keyword>venous thrombosis</keyword>
	<keyword>thrombosis risk factor</keyword>
	<keyword>thrombophilia</keyword>
</DOC>